SCHEMBL4679719

SCHEMBL4679719

O=C(C=C(O)c1nn[nH]n1)c1ccn(S(=O)(=O)c2ccc(Cl)cc2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.38
AKR1C1 Q04828 1/20 0.38
CYP2C19 P33261 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CNKSR1 Q969H4 1/20 0.33
PSEN1 P49768 3/20 0.32
PSEN2 P49810 3/20 0.32
APH1B Q8WW43 3/20 0.32
NCSTN Q92542 3/20 0.32
APH1A Q96BI3 3/20 0.32
PSENEN Q9NZ42 3/20 0.32
CXCR3 P49682 1/20 0.32
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.30
GRM4 Q14833 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673146 0.90 AKR1C3 (0.38) AKR1C3AKR1C1CYP2C19KMT2ACYP3A4
SCHEMBL4674101 0.83 AKR1C3 (0.38) AKR1C3AKR1C1CYP2C19MEN1KMT2A
SCHEMBL4672618 0.80 CXCR3 (0.35) AKR1C3MEN1KMT2ASMN1; SMN2PSEN1
SCHEMBL4677991 0.79 ALDH1A1 (0.51) AKR1C3CYP2C19PSEN1PSEN2APH1B
SCHEMBL4672248 0.79 RAPGEF4 (0.39) AKR1C3CYP2C19MEN1KMT2APSEN1
SCHEMBL4675007 0.79 AKR1C3 (0.44) AKR1C3AKR1C1CYP2C19MEN1KMT2A
SCHEMBL4679426 0.77 ALDH1A1 (0.39) AKR1C3CYP2C19MEN1KMT2ACYP3A4
SCHEMBL4675352 0.75 CMA1 (0.34) AKR1C3CYP2C19CXCR3ALDH1A1LMNA
SCHEMBL4673202 0.75 CA2 (0.34) AKR1C3CYP2C19CXCR3ALDH1A1LMNA
SCHEMBL4670921 0.74 CXCR3 (0.31) MEN1KMT2ACYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1C3 30/4885AKR1C1 25/4885CYP2C19 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.